ArticleBritish journal of cancer2020

Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer.

Robin M J M van Geel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.